Evidence map›Paper›PMID 38310020›Full record

ReviewTrends in biotechnology2024

Novel delivery systems for controlled release of bacterial therapeutics.

Nadia Zaragoza, Grace I Anderson, Stephanie Allison-Logan, Kirmina Monir, Ariel L Furst

Abstract readReview
In one paragraph

Review in Trends in biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nadia ZaragozaDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Grace I AndersonDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Stephanie Allison-LoganDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Kirmina MonirDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Ariel L FurstDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Center for Environmental Health Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic address: afurst@mit.edu.

Funding

TOXICOLOGY CORE UNITP30ES002109 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI NILES, JACQUIN C · 1985 to 2020
$25.6M
The MIT Superfund Research Program: A Systems Approach for the Protection of Human Health from Hazardous ChemicalsP42ES027707 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Stuart S Levine · 2017 to 2026
$22.2M
Protecting microbes so they can protect usDP2GM154015 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Ariel Lesa Furst · 2023 to 2026
$2.4M
NIEHS NIH HHS P30 ES002109NIEHS NIH HHS P42 ES027707NIGMS NIH HHS DP2 GM154015
6 · The paper itself

Abstract

As more is learned about the benefits of microbes, their potential to prevent and treat disease is expanding. Microbial therapeutics are less burdensome and costly to produce than traditional molecular drugs, often with superior efficacy. Yet, as with most medicines, controlled dosing and delivery to the area of need remain key challenges for microbes. Advances in materials to control small-molecule delivery are expected to translate to microbes, enabling similar control with equivalent benefits. In this perspective, recent advances in living biotherapeutics are discussed within the context of new methods for their controlled release. The integration of these advances provides a roadmap for the design, synthesis, and analysis of controlled microbial therapeutic delivery systems.

Indexed as

Delayed-Action PreparationsDrug Delivery SystemsAnti-Bacterial AgentsBacteriaHumansAnti-Bacterial AgentsDelayed-Action Preparationsbiopolymersdrug deliveryliving biotherapeutics

Identifiers

PMID38310020
PMCPMC12404607

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.